CBS 2019
CBSMD教育中心
中 文

Cardio-Oncology

Abstract

Recommended Article

ACS Management in a Patient in Need of Noncardiac Surgery Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy Risk of Cardiovascular Diseases Among Older Breast Cancer Survivors in the United States: A Matched Cohort Study Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction Cardiovascular effects of radiation therapy Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma Cardio-Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio-Oncology council Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
|<< 1 2 3 4 5 >>|

Original Research2020 Jul 27.

JOURNAL：Neuroendocrinology. Article Link

Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications

M Liu, E Armeni, S Navalkissoor et al. Keywords: adenosine; arthritis; ticagrelor vs. clopidogrel; osteoarthritis

ABSTRACT

BACKGROUND - Cardiac metastases (CM) from neuroendocrine tumours (NET) are rare, however with the introduction of new molecular imaging modalities, such as 68Ga-DOTATATE PET-CT for NET diagnosis and re-staging, they are now identified more frequently. This study presents a single-institution experience on the NET CM characteristics, management and prognostic implications.


METHODS - Between January 1998 and January 2020, 25 NET patients with CM were treated in our Unit. A retrospective review of electronic records was performed. Overall survival (OS) was assessed by the Kaplan-Meier method. Cox regression models were used to evaluate the association of various clinical variables with OS.


RESULTS - The median age in the NET CM cohort was 64 years, with small intestine being the most common primary (84%). Nearly half of the patients suffered either from shortness of breath (48%) or had palpitations (12%). Peptide Receptor Radionuclide Therapy (PRRT) was applied in more than half of the patients (64%), who had an improved-trend for a longer median OS compared to those patients who did not receive PRRT (76.0 vs. 14.0 months, p = 0.196). The multivariate analysis demonstrated that concomitant skeletal or pancreatic metastases, as well as N-terminal Pro-B-type Natriuretic Peptide (NT pro-BNP) > 2 × upper limit of normal (ULN) were independent poor prognosticators.


CONCLUSIONS - Clinical features of NET CM ranged from asymptomatic patients to heart failure. Concomitant bone or pancreatic metastases and NT pro-BNP levels > 2 ULN predicted shorter survival time. PRRT serves as a feasible therapy with promising survival benefits, however more data are needed.


© 2020 S. Karger AG, Basel.

>CBS CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

 CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

> PRE-READING

CBS 2019 CBS 2019 FACULTY Education Resource CBSMD Scientific Library
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top